• 1:中国医师协会心血管分会结构性心脏病学组

摘要(Abstract)：

近年来，随着结构性心脏病领域的迅猛发展，介入治疗经历了从稚嫩到成熟、由探索到创新的跨越历程，各种新型介入手段和器械层出不穷，给广大结构性心脏病患者带来了新的曙光。知往鉴今，以启未来，2023年结构性心脏病介入治疗年度报告系统性回顾了过去一年中结构性心脏病介入治疗领域的新理念、新器械、新研究、新指南等，涵盖了国内外的最新进展，剖析了存在的问题及未来的方向，以促进结构性心脏病领域规范化发展。

关键词(KeyWords)： 结构性心脏病;介入治疗;年度报告

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（82200062、82270377）;; 上海市科委启明星项目扬帆专项项目（22YF1439500）

作者(Author):

参考文献(References)：

• [1]葛均波.迎接我国结构性心脏病介入治疗的新时代[J].中国介入心脏病学杂志,2021,29(2):61-62.DOI:10.3969/j.issn.1004-8812.2021.02.001.
• [2] Mack MJ,Leon MB,Thourani UH,et al.Trans catheter aortic-valve replacement in low-risk patients at five years[J].N Engl J Med,2023,389(21):1949-1960.DOI:10.1056/NEJMoa2307447.
• [3]Forrest JK,Deeb GM,Yakubov SJ,et al.4-Year outcomes of patients with aortic stenosis in the evolut low risk trial[J].J Am Coll Cardiol,2023,82(22):2163-2165.DOI:10.1016/j.jacc.2023.09.813.
• [4] Madhavan MV,Kodali SK,Thourani VH,et al.Outcomes of SAPIEN 3 Transcatheter aortic valve replacement compared with surgical valve replacement in intermediate-risk patients[J].J Am Coll Cardiol,2023,82(2):109-123.DOI:10.1016/j.jacc.2023.04.049.
• [5] O'Hair D,Yakubov SJ,Grubb KJ,et al.Structural valve deterioration after self-expanding transcatheter or surgical aortic valve implantation in patients at intermediate or high risk[J].JAMA Cardiol,2023,8(2):111-119.DOI:10.1001/jamacardio.2022.4627.
• [6] Okuno T,Tomii D,Lanz J,et al.5-Year outcomes with self-expanding vs balloon-expandable transcatheter aortic valve replacement in patients with small annuli[J].JACC Cardiovasc Interv,2023,16(4):429-440.DOI:10.1016/j.jcin.2022.11.032.
• [7] Rodes-Cabau J,Ribeiro HB,Mohammadi S,et al.Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus:a randomized clinical trial[J].Circulation,2024,149(9):644-655.DOI:10.1161/CIRCULATIONAHA.123.066732.
• [8] Galper BZ,Chinnakondepalli KM,Wang K,et al.Economic outcomes of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis and low surgical risk:results from the PARTNER 3 trial[J].Circulation,2023,147(21):1594-1605.DOI:10.1161/CIRCULATIONAHA.122.062481.
• [9] Ryffel C,Windecker S,Pilgrim T.Expansion o f transcatheter aortic valve implantation and mortality due to aortic stenosis between 2010 and 2019[J].Circ Cardiovasc Interv,2023,16(12):e013104.DOI:10.1161/CIRCINTERVENTIONS.123.013104.
• [10]Reindl M,Lechner I,Holzknecht M,et al.Cardiac magnetic resonance imaging versus computed tomography to guide transcatheter aortic valve replacement:a randomized,open-label,noninferiority trial[J].Circulation,2023,148(16):1220-1230.DOI:10.1161/CIRCULATIONAHA.123.066498.
• [11]Grubb KJ,Shekiladze N,Spencer J,et al.Feasibility of redoTAVI in self-expanding Evolut valves:a CT analysis from the evolut low risk trial sub study[J].Euro Intervention,2023,19(4):e330-e339.DOI:10.4244/EIJ-D-22-01125.
• [12]Tang GHL,Spencer J,Rogers T,et al.Feasibility of coronary access following Redo-TAVR for evolut failure:a computed tomography simulation study[J].Circ Cardiovasc Interv,2023,16(11):e013238.DOI:10.1161/CIRCINTERVENTIONS.123.013238.
• [13]Kodali SK,Sorajja P,Meduri CU,et al.Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve-DurAVR[J].EuroIntervention,2023,19(4):e352-e362.DOI:10.4244/EIJ-D-23-00282.
• [14] Garcia S.Ye J,Webb J,et al.Transcatheter treatment of native aortic valve regurgitation:the north american experience with a novel device[J].JACC Cardiovasc Interv,2023,16(16):1953-1960.DOI:10.1016/j.jcin.2023.05.018.
• [15] Vahl TP,Thourani VH,Makkar RR,et al.Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation(ALIGN-AR):a prospective,multicentre,single-arm study[J].Lancet,2024.DOI:10.1016/S0140-6736(23)02806-4.
• [16]Messas E,IjsselmuidenA,Trifunovic-Zamaklar D,et al.Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy:a cohort study[J].Lancet,2023,402(10419):2317-2325.DOI:10.1016/S0140-6736(23)01518-0.
• [17]Regueiro A,Alperi A,Vilalta V,et al.Safety and efficacy of TAVR with a pressure sensor and pacing guidewire:SAFE-TAVI TRIAL[J].JACC Cardiovasc Interv,2023,16(24):3016-3023.DOI:10.1016/j.jcin.2023.10.035.
• [18]国家心血管病中心,国家结构性心脏病介入质控中心,中华医学会心血管病学分会,等.经导管主动脉瓣置换术临床实践指南[J].中华医学杂志,2023,103(12):886-900.DOI:10.3760/cma.j.cn112137-20221106-02332.
• [19]石峻,赵元,郭应强.心尖入路经导管主动脉瓣植入手术操作规范[J].中国胸心血管外科临床杂志,2023,30(4):491-500.DOI:10.7507/1007-4848.202302011.
• [20]张海波,侯晓彤,郭应强.心尖途径经导管主动脉瓣置换术围术期管理规范专家建议[J].中国胸心血管外科临床杂志,2023,30(7):927-935.DOI:10.7507/1007-4848.202304023.
• [21]广东省医学会心血管病学分会介入心脏病学组,海南省医学会心血管病专业委员会,张海峰,等.经皮主动脉瓣置入患者冠状动脉粥样硬化性心脏病管理专家共识[J].中国临床研究,2023,36(11):1605-1612.DOI:10.13429/j.cnki.cjcr.2023.11.001.
• [22]中国医疗保健国际交流促进会胸痛学分会,山东省医学会心肺复苏与体外生命支持多学科联合委员会,《体外膜肺氧合辅助循环崩溃高风险经导管主动脉瓣置换术技术要点专家共识》专家组.体外膜肺氧合辅助循环崩溃高风险经导管主动脉瓣置换术技术要点专家共识[J].中国介入心脏病学杂志,2023,31(11):810-819.DOI:10.3969/j.issn.1004-8812.2023.11.002.
• [23]中国医师协会心血管内科医师分会结构性心脏病学组,周达新,吴永健.单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023[J].中国介入心脏病学杂志,2023,31(11):801-809.DOI:10.3969/j.issn.1004-8812.2023.11.001.
• [24]Ge J,Zhou D,Zhang X,et al.Preliminary implantation of a novel TAVR device with polymeric leaflets for symptomatic calcific aortic disease[J].JACC Case Rep,2023,17:101901.DOI:10.1016/j.j accas.2023.101901.
• [25]Chen S,Lin D,Qi Y,et al.A transcatheter"sandwich"valve-in-valve implantation for pure aortic regurgitation:a report of 2 cases[J].Cardiology Plus,2023,8(3):211-215.DOI:10.1097/cp9.0000000000000059.
• [26]Pan WZ,Lin DW,Chen SS,et al.Transcatheter"sandwich"valve-in-valve implantation technique for pure aortic regurgitation:operation skills and early experience[J].Cardiovasc Innov Appl,2024,9(1).DOI:10.15212/cvia.2024.0007.
• [27] Stone GW,Abraham WT,Lindenfeld J,et al.Fiveyear follow-up after transcatheter repair of secondary mitral regurgitation[J].N Engl J Med,2023,388(22):2037-2048.DOI:10.1056/NEJMoa2300213.
• [28]Makkar RR,Chikwe J,Chakravarty T,et al.Transcatheter mitral valve repair for degenerative mitral regurgitation[J].JAMA,2023,329(20):1778-1788.DOI:10.1001/jama.2023.7089.
• [29]von Bardeleben RS,Mahoney P,Morse MA,et al.1-Year outcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from the EXPAND G4 study[J].JACC Cardiovasc Interv,2023,16(21):2600-2610.DOI:10.1016/j.jcin.2023.09.029.
• [30]Saji M,Yamamoto M,Kubo S,et al.Short-term outcomes following transcatheter edge-to-edge repair:insights from the OCEAN-mitral registry[J].JACC Asia,2023,3(5):766-773.DOI:10.1016/j.jacasi.2023.06.008.
• [31] Kubo S,Yamamoto M,Saji M,et al.One-year outcomes and their relationship to residual mitral regurgitation after transcatheter edge-to-edge repair with mitraclip device:insights from the OCEAN-mitral registry[J].J Am Heart Assoc,2023,12(20):e030747.DOI:10.1161/JAHA.123.030747.
• [32]Zahr F,Smith RL,Gillam LD,et al.One-year outcomes from the CLASP IID randomized trial for degenerative mitral regurgitation[J].JACC Cardiovasc Interv,2023:S1936-8798(23)01358-4.DOI:10.1016/j.jcin.2023.1010.1002.
• [33]Pan W,Long Y,Guo Y,et al.Transapical edge-to-edge repair system in high-risk patients with degenerative mitral regurgitation:a multicenter trial(CLAMP-2)[J].JACC Cardiovasc Interv,2023,16(18):2340-2342.DOI:10.1016/j.jcin.2023.06.035.
• [34]Wang JA,Liu X,Pu Z,et al.Safety and efficacy of the DragonFly system for transcatheter valve repair of degenerative mitral regurgitation:one-year results of the DRAGONFLY-DMR trial[J].EuroIntervention,2024,20(4):e239-e249.DOI:10.4244/eij-d-23-00361.
• [35]Guerrero M.Outcomes of mitral valve-in-valve,valve-in-ring and valve-in-mitral annular calcification:prospective MITRAL(Mitral Implantation of TRAnscatheter vaLves)Trial final results[C].Presented at:EuroPCR 2023.Paris,France.2023.
• [36]Ludwig S,Kalbacher D,Ali WB,et al.Transcatheter mitral valve replacement or repair for secondary mitral regurgitation:a propensity score-matched analysis[J].Eur J Heart Fail,2023,25(3):399-410.DOI:10.1002/ejhf.2797.
• [37]Ludwig S,Conradi L,Cohen D J,et al.Transcatheter mitral valve replacement versus medical therapy for secondary mitral regurgitation:a propensity score-matched comparison[J].Circ Cardiovasc Interv,2023,16(6):e013045.DOI:10.1161/CIRCINTERVENTIONS.123.013045,
• [38] Ueyama HA,Miyamoto Y,Watanabe A,et al.Cardiac reoperation or transcatheter mitral valve replacement for patients with failed mitral prostheses[J].J Am Coll Cardiol,2024,83(2):317-330.DOI:10.1016/j.jacc.2023.10.014.
• [39]Zahr F,Song HK,Chadderdon S,et al.1-Year outcomes following transfemoral transseptal transcatheter mitral valve replacement:intrepid TMVR early feasibility study results[J].JACC Cardiovasc Interv,2023,16(23):2868-2879.DOI:10.1016/j.jcin.2023.10.001.
• [40]Otto CM,Nishimura RA,Bonow RO,et al.2020 ACC/AHA guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].J Am Coll Cardiol,2021,77(4):450-500.DOI:10.1016/j.jacc.2020.11.035.
• [41]Vahanian A,Beyersdorf F,Praz F,et al.2021 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2022,43(7):561-632.DOI:10.1093/eurheartj/ehab395.
• [42]中国医师协会心血管内科医师分会结构性心脏病学组,亚太结构性心脏病俱乐部.中国经导管二尖瓣缘对缘修复术临床路径(2022版)精简版[J].中国介入心脏病学杂志,2023,31(3):161-173.DOI:10.3969/j.issn.1000-3614.2023.03.002.
• [43]中国医师协会心血管内科医师分会,中国康复医学会心脏介入治疗和康复专业委员会,中国医院协会心脏康复管理专业委员会.经导管二尖瓣缘对缘修复术患者心脏康复中国专家共识[J].中国介入心脏病学杂志,2023,31(4):252-265.DOI:10.3969/j.issn.1004-8812.2023.04.002.
• [44]Kodali S,Hahn RT,Makkar R,et al.Transfemoral tricuspid valve replacement and one-year outcomes:the TRISCEND study[J].Eur Heart J,2023,44(46):4862-4873.DOI:10.1093/eurheartj/ehad667.
• [45] Teiger E,Nejjari M,Lim P,et al.First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system[7].EuroIntervention,2022,18(10):862-864.DOI:10.4244/EIJ-D-22-00277.
• [46] Blasco-Turrion S,Briedis K,Estevez-Loureiro R,et al.Bicaval tricvalve implantation in patients with severe symptomatic tricuspid regurgitation:1-year follow-up outcomes[J].JACC Cardiovasc Interv,2024,17(1):60-72.DOI:10.1016/j.jcin.2023.10.043.
• [47]Lurz P,Besler C,Schmitz T,et al.Short-term outcomes of tricuspid edge-to-edge repair in clinical practice[J].J Am Coll Cardiol,2023,82(4):281-291.DOI:10.1016/j.jacc.2023.05.008.
• [48]Arnold SV,Goates S,Sorajja P,et al.Health status after transcatheter tricuspid-valve repair in patients with severe tricuspid regurgitation[J].J Am Coll Cardiol,2024,83(1):1-13.DOI:10.1016/j.jacc.2023.10.008.
• [49]Sorajja P,Whisenant B,Hamid N,et al.Transcatheter repair for patients with tricuspid regurgitation[J].N Engl J Med,2023,388(20):1833-1842.DOI:10.1056/NEJMoa2300525.
• [50] Kodali SK,Hahn RT,Davidson CJ,et al.1-Year outcomes of transcatheter tricuspid valve repair[J].J Am Coll Cardiol,2023,81(18):1766-1776.DOI:10.1016/j.jacc.2023.02.049.
• [51]Planer D,Beeri R,Danenberg HD.First-in-human transcatheter tricuspid valve repair:30-day follow-up experience with the mistral device[J].JACC Cardiovasc Interv,2020,13(18):2091-2096.DOI:10.1016/j.jcin.2020.05.050.
• [52]Danenberg HD,Topilsky Y,Planer D,et al.Tricuspid valve repair by chordal grasping:mistral first-in-human trial results at6 months[7].JACC Cardiovasc Interv,2023,16(2):244-246.DOI:10.1016/j.jcin.2022.09.035.
• [53]Piayda K,Bertog S,Steffan J,et al.One-year outcomes of transcatheter tricuspid valve repair with the Mistral device[J].Euro Intervention,2023,19(4):e363-e365.DOI:10.4244/EIJ-D-22-01032.
• [54]Cmics Obo,Wang C,Wei L,et al.2022 CMICS expert consensus on the management of isolated tricuspid regurgitation after left-sided valve surgery[J].Rev Cardiovasc Med,2023,24(5):129.DOI:10.31083/j.rcm2405129.
• [55]Adamo M,Chioncel O,Pagnesi M,et al.Epidemiology,pathophysiolo gy,diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation.A clinical consensus statement of the Heart Failure Association(HFA)and the European Association of Percutaneous Cardiovascular Interventions(EAPCI)of the ESC[J].Eur J Heart Fail,2024,26(1):18-33.DOI:10.1002/ejhf.3106.
• [56]Zhang Y,Lu F,Li W,et al.A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system[J].EuroIntervention,2023,18(13):e1088-e1089.DOI:10.4244/EIJ-D-22-00517.
• [57]Pan W,Long Y,Zhang X,et al.Feasibility study of a novel transcatheter tricuspid annuloplasty system in a porcine model[J].JACC Basic Transl Sci,2022,7(6):600-607.DOI:10.1016/j.jacbts.2022.02.022.
• [58]Zhang X,Jin Q,Pan W,et al.First-in-human study of the K-Clip transcatheter annular repair system for severe functional tricuspid regurgitation[J].Int J Cardiol,2023,390:131174.DOI:10.1016/j.ijcard.2023.131174.
• [59]Freeman TV.Long-term outcomes following left atrial appendage occlusion with a watchman device:outcomes from the national cardiovascular data registry[M].Presented at:ESC Congress2023.Amsterdam,Netherlands.2023.
• [60] Merdler I,Reddy PK,Bhogal S,et al.Review of latebreaking trials from CRT 2023[J].Cardiovasc Revasc Med,2023,53S:S3-S9.DOI:10.1016/j.carrev.2023.04.017.
• [61]Lakkireddy D,Thaler D,Ellis CR,et al.3-year outcomes from the amplatzer amulet left atrial appendage occluder randomized controlled trial(Amulet IDE)[J].JACC Cardiovasc Interv,2023,16(15):1902-1913.DOI:10.1016/j.jcin.2023.06.022.
• [62]Galea R,Meneveau N,De Marco F,et al.One-year outcomes after amulet or watchman device for percutaneous left atrial appendage closure:a prespecified analysis of the SWISS-APERO randomized clinical trial[J].Circulation,2024,149(6):484-486.DOI:10.1161/CIRCULATIONAHA.123.067599.
• [63] Kapadia SR,Krishnaswamy A,Whisenant B,et al.Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation[J].Circulation,2023.DOI:10.1161/CIRCULATIONAHA.1123.067312.
• [64] Saliba WI,Kawai K,Sato Y,et al.Enhanced thromboresistance and endothelialization of a novel fluoropolymer-coated left atrial appendage closure device[J].JACC Clin Electrophysiol,2023,9(8Pt2):1555-1567.DOI:10.1016/j.jacep.2023.04.013.
• [65]Wong GX,Kar S,Smith TW,et al.Transcatheter left atrial appendage exclusion:preclinical and early clinical results with the laminar device[J].JACC Cardiovasc Interv,2023,16(11):1347-1357.DOI:10.1016/j.jcin.2023.04.028.
• [66] Saw J,Holmes DR,Cavalcante JL,et al.SCAI/HRS Expert consensus statement on transcatheter left atrial appendage closure[J].JACC Cardiovasc Interv,2023,16(11):1384-1400.DOI:10.1016/j.j cin.2023.01.011.
• [67]Joglar JA,Chung MK,Armbruster AL,et al.2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].J Am Coll Cardiol,2024,83(1):109-279.DOI:10.1016/jjacc.2023.08.017.
• [68]中华医学会心血管病学分会,中国生物医学工程学会心律分会.心房颤动诊断和治疗中国指南[J].中华心血管病杂志,2023,51(6):572-618.DOI:10.3760/cmaj.cn112148-20230416-00221.
• [69]Jiang ZZ,Lin YZ,Zhang JC.Cryoablation combined with percutaneous left atrial appendage closure for nonvalvular atrial fibrillation:a follow-up result[J].Minerva Med,2023.DOI:10.23736/S0026-4806.23.08697-4.Online ahead of print.
• [70]Fei X,Wang B,Chu H,ct al.Clinical outcomes of combined catheter ablation and left atrial appendage closure in elderly patients with nornvalvular atrial fibrillation[J].Clin Cardiol,2024,47(1):e24169.DOI:10.1002/clc.24169.
• [71]Zhang Y,Yang J,Liu Q,et al.Comparison of adverse events between isolated left atrial appendage closure and combined catheter ablation[J].J Clin Med,2023,12(5):1824.DOI:10.3390/jcm12051824.
• [72]黄青云,李文彦,杨曼,等.射频消融联合左心耳封堵治疗非瓣膜性心房颤动的长期有效性及安全性研究[J].临床心血管病杂志,2023,39(7):541-546.DOI:10.13201/j.issn.1001-1439.2023.07.010.
• [73]胡一东.导管消融联合左心耳封堵一站式治疗非瓣膜性房颤的临床研究[D].安徽:皖南医学院,2023:1-26.
• [74]Chen Y,Chen Y,Lam YY,et al.Intracardiac echocardiographic imaging with a cartosound module for guidance of left atrial appendage closure:a comparative study with transesophageal echocardiographic imaging[J].Int J Cardiovasc Imaging,2023,39(9):1667-1675.DOI:10.1007/s 10554-023-02880-4.
• [75] Zhang ZY,Li F,Zhang J,et al.A comparable efficacy and safety between intracardiac echocardiography and transesophageal echocardiography for percutaneous left atrial appendage occlusion[J].Front Cardiovasc Med,2023,10:1194771.DOI:10.3389/fcvm.2023.1194771.
• [76]Ding X,Xiang K,Qian C,et al.Intracardiac echocardiography is a promising strategy for guiding closure of the left atrial appendage[J].Health Sci Rep,2023,6(12):e1762.DOI:10.1002/hsr2.1762.
• [77]Yan C,Li H,Wang C,et al.Frequency and size of In Situ thrombus within patent foramen ovale[J].Stroke,2023,54(5):1205-1213.DOI:10.1161/STROKEAHA.122.041524.
• [78] Kamran MM,Gopi A,Lakhani Z,et al.Utility of konarmultifunctional occluder in complex situations:unconventional uses in rare situations[J].Pediatr Cardiol,2024,45(1):121-132.DOI:10.1007/s00246-023-03358-9.
• [79]王思宝,泮思林,罗刚,等.经导管肺动脉瓣打孔术治疗新生儿室间隔完整型肺动脉闭锁临床分析[J].中华儿科杂志,2023,61(2):126-130.DOI:10.3760/cma.j.cn112140-20220622-00578.
• [80]焦先婷,赵莉晴,沈加,等.动脉导管支架置入术治疗不同类型新生儿肺动脉闭锁的随访结局[J].中华儿科杂志,2023,61(2):136-140.DOI:10.3760/cma.j.cn112140-20221104-00934.
• [81]李棣文,赵天力,胡世军,等.改良Blalock-Taussig分流术与右心室流出道支架置入术姑息性治疗法洛四联症的比较[J].中南大学学报(医学版),2023,48(9):1325-1332.DOI:10.11817/j.issn.1672-7347.2023.230105.
• [82]Guo H.Wu Z,Zhao T,et al.Right ventricular outflow tract stenting promotes pulmonary artery development in tetralogy of fallot[J].Front Surg,2023,10:1056772.DOI:10.3389/fsurg.2023.1056772.
• [83]李翔,李晓,李侨,等.介入主动脉支架桥接外科矫治术治疗危重新生儿主动脉缩窄1例[J].中国介入心脏病学杂志,2023,31(9):714-716.DOI:10.3969/j.issn.1004-8812.2023.09.014.
• [84]Zhang H,Kan J,Zhang J,et al.3-year outcome in patients with combined precapillary and postcapillary pulmonary hypertension:results from PADN-5 trial[J].JACC Heart Fail,2023,11(8 Pt 2):1135-1146.DOI:10.1016/j.jchf.2023.05.016.
• [85] Kan J,Zhang H,Xie D,et al.A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension:one-year outcomes of the PADN-CFDA trial[J].Euro Intervention,2023,19(8):684-694.DOI:10.4244/EIJ-D-23-00349.
• [86]Zhang J,Kan J,Wei Y,et al.Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score:results from PADN-CFDA trial[J].J Heart Lung Transplant,2023,42(8):1140-1151.DOI:10.1016/j.healun.2023.03.015.
• [87]Valdeolmillos E,Le Pavec J,AudiéM,et al.Thirty years of surgical management of pediatric pulmonary hypertension:mid-term.outcomes following reverse Potts shunt and transplantation[J].J Thorac Cardiovasc Surg,2023:S0022-5223(23)01121-2.DOI:10.1016/j.jtcvs.2023.11.045.
• [88]Yang L,Guan L,Chen D,et al.Impact of current targeted drug therapy on the prognosis of Eisenmenger syndrome:a large-scale retrospective analysis[J].Hellenic J Cardiol,2023,72:9-14.DOI:10.1016/j.hjc.2023.03.004.
• [89]Xie F,Quan R,Zhang G,et al.Characteristics,treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China:insights from a national multicenter prospective registry[J].J Heart Lung Transplant,2023,42(7):974-984.DOI:10.1016/j.healun.2023.02.1494.
• [90]中国医师协会心血管内科医师分会结构性心脏病学组,心源性脑脑卒中人群的高危预测模型及治疗策略的临床研究课题组.卵圆孔未闭超声诊断中国专家共识[J].中国介入心脏病学杂志,2023,31(1):4-11.DOI:10.3969/j.issn.1004-8812.2023.01.002.
• [91]中国人体健康科技促进会结构性心脏病专委会,中国医师协会神经内科分会.卵圆孔未闭相关非卒中性疾病防治中国专家共识[J].心脏杂志,2024,36(2):125-134.DOI:10.12125/j.chj.202307041.
• [92]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.肺静脉狭窄诊治中国专家共识[J].中华心血管病杂志,2023,51(9):930-943.DOI:10.3760/cma.j.cnl 12148-20230516-00274.
• [93] Jone PN,Ivy DD,Hauck A,et al.Pulmonary hypertension in congenital heart disease:a scientific statement from the American Heart Association[J].Circ Heart Fail,2023,16(7):e00080.DOI:10.1161/HHF.000000000000080.
• [94]国家心血管病中心肺动脉高压专科联盟国家,心血管病专家委员会右心与肺血管病专业委员会.中国肺动脉高压诊治临床路径[J].中国循环杂志,2023,38(7):691-703.DOI:10.3969/j.issn.1000-3614.2023.07.002.
• [95]常开丽,张灿,徐云燕,等.3D打印技术在先天性心脏病诊疗中的应用现状[J].中国介入心脏病学杂志,2023,31(4):304-309.DOI:10.3969/j.issn.1004-8812.2023.04.009.